Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Highly sensitive detection of ESR1 mutations in cell-free DNA from patients with metastatic breast cancer using molecular barcode sequencing.

Breast cancer research and treatment - 1 Jan 2018

Masunaga Nanae, Kagara Naofumi, Motooka Daisuke, Nakamura Shota, Miyake Tomohiro, Tanei Tomonori, Naoi Yasuto, Shimoda Masafumi, Shimazu Kenzo, Kim Seung Jin, Noguchi Shinzaburo

Abstract excerpt

PURPOSE: We aimed to develop a highly sensitive method to detect ESR1 mutations in cell-free DNA (cfDNA) using next-generation sequencing with molecular barcode (MB-NGS) targeting the hotspot segment (c.1600-1713). METHODS: The sensitivity of MB-NGS was tested using serially diluted ESR1 mutant DNA and then cfDNA samples from 34 patients with metastatic breast cancer were analyzed with MB-NGS. The results of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Cell-Free Nucleic Acids

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Barcoding, Taxonomic

Share to DNA, Neoplasm

Share to Estrogen Receptor alpha

Share to Gene Frequency

Share to High-Throughput Nucleotide Sequencing

Share to Neoplasm Metastasis

Source

Identifiers

PMID: 28905136
DOI: 10.1007/s10549-017-4487-y

Genes

ESR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Highly sensitive detection of ESR1 mutations in cell-free DNA from patients with metastatic breast cancer using molecular barcode sequencing.PMID 28905136Read ↗

ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study.Semantic proximity Read ↗

Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.Semantic proximity Read ↗

Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens.Semantic proximity Read ↗

ESR1 Mutations in Breast Cancer: Proof-of-Concept Challenges Clinical Action.Semantic proximity Read ↗

Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients.Semantic proximity Read ↗

Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patientsSemantic proximity Read ↗

Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer PatientsSemantic proximity Read ↗

Sensitive quantitation of ESR1 mutations in cell-free DNA from breast cancer patients using base-specific invasive reaction assisted qPCR.Semantic proximity Read ↗

Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing.Semantic proximity Read ↗

Detection of ESR1 Mutations in Tissue and Liquid Biopsy with Novel Next-Generation Sequencing and Digital Droplet PCR Assays: Insights from Multi-Center Real Life Data of Almost 6000 PatientsSemantic proximity Read ↗

High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy.Semantic proximity Read ↗

Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.